Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

11 Jan 2023

Algernon Pharmaceuticals Announces Plans for 180 Patient Phase 2b Study

Algernon continues to move its programs forward, as it announces plans for a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3...

By Microdose NewsDesk

Industry

10 Jan 2023

Reunion Neuroscience Completes Data Analysis for Phase 1 Clinical Trial

Reunion Neuroscience Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104...

By Microdose NewsDesk

Culture

9 Jan 2023

Prince Harry Admits Psychedelics Helped His Mental Health

Prince Harry has admitted that psychedelics have helped him get through some personal trauma and mental health issues...

By Microdose NewsDesk

Industry

9 Jan 2023

Secretive GH Research Provides Business Updates and Upcoming Milestones

Secretive psychedelic drug developments firm GH Research has released its most recent business update and upcoming milestones....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

5 Jan 2023

MAPS’ Positive Results Confirmed in Second Phase 3 Trial

MAPS has announced that the second part of its Phase 3 trial of MDMA-assisted therapy for PTSD has confirmed prior positive trial results....

By Microdose NewsDesk

Finance, Industry

3 Jan 2023

Algernon Forms Private Subsidiary to Advance DMT Stroke Program

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program...

By Microdose NewsDesk

Industry

27 Dec 2022

2022 End of Year Review: Small Pharma

Continuing our end-of-year review, we’ll take a moment to update DMT company Small Pharma’s last 12 months....

By Microdose NewsDesk

Industry

23 Dec 2022

atai Life Sciences Announces Results of Phase 1 Trial for KUR-101

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101...

By Microdose NewsDesk

Industry

22 Dec 2022

Small Pharma Completes Phase IIa Trial and Secures New IP

DMT-development firm Small Pharma has moved its lead candidate drug further through the clinical trial process with the completion of its Phase 2a trial....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.